Centre Leon Berard, Lyon
Insitut Claudius Regauld, Toulouse
Gustave Roussy, Villejuif
Consider ARROW - a clinical trial of BLU-667 for RET-altered non-small cell lung cancer (NSCLC), medullary thyroid cancer (MTC) and other RET-altered cancers.
The ARROW clinical trial will test an investigational drug called BLU-667 in people who have RET-altered non-small cell lung cancer (NSCLC), medullary thyroid cancer (MTC) or another solid tumor that has a RET fusion or mutation. It is a phase 1 trial designed to test the safety and the initial clinical activity of BLU-667.
Information about RET-altered cancers
All cancers begin when one or more genes are mutated (altered) and the cell starts to divide and grow out of control. Identifying these genes is important, because drugs can be developed to target them.
RET fusions and mutations are specific alterations that are sometimes found in a gene called RET. This gene provides the instructions for making the RET protein that is involved in important cell functions. RET alterations have been shown to cause non-small cell lung cancer, medullary thyroid cancer and other solid tumors in some people. BLU-667 is an investigational drug that was specifically designed to inhibit (block) altered forms of RET.
You may be eligible to take part in the ARROW clinical trial if you:
Have non-small cell lung cancer (NSCLC) with a known RET fusion or mutation
Have medullary thyroid cancer (MTC). A known RET alteration is not required
Have another solid tumor with a known RET fusion or mutation
Are at least 18 years old
Are not eligible for surgery and have exhausted all standard therapy options
Other eligibility criteria apply and these will be assessed at screening
RET fusions and mutations may be identified by your doctor with a tumor biopsy or a blood test
If you take part in the ARROW clinical trial, you would receive the investigational drug BLU-667. BLU-667 comes in a capsule or tablet form, and should be swallowed whole with water, once a day.
Up to 28 days
To assess your suitability for the trial.
All participants will receive the investigational drug for a minimum of 28 days (1 cycle).
Follow up period
All participants must have a follow-up visit 14 days after their last dose of investigational drug. At 30 days, we will give participants a follow-up call and then again every 3 months until disease progression.
*There is no maximum duration for this trial. You will continue with your cycles of treatment until:
During the trial, a variety of health assessments will be conducted to see how you are responding to the investigational drug. In most cases, these assessments will be done at a clinical site.
Health assessments will vary between visits, but may include:
More information about health assessments and visit length will be found in the informed consent form, which you will need to read and sign if you want to take part in the ARROW clinical trial.
How often will these visits take place?*
Cycle 3 onwards
Once per cycle
*Please note that these numbers are approximate. One treatment cycle is 28 days.
Please enter your city, ZIP Code, or country to find a trial site near you, or see the full site list.
A travel support program is available for participants and caregivers at most trial sites to reduce out-of-pocket expenses and help ensure travel to the trial site is simple and comfortable. More information about travel support is provided by the trial site during the screening process.